Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in five FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, pain and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.
$369.61 0.51 (0.14)%
Market Cap 38.50B
04/24/17 12:48 PM ET | Minimum 20 minutes delay.
Stock information provided by eSignal.
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid ArthritisRead on
Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017Read on
Regeneron Pharmaceuticals Q1 2017 Earnings Conference Call
May 4, 2017 | 8:30 AM
2017 Annual Meeting of Shareholders
Jun 9, 2017 | 10:30 AM ET